EUVIMEDEUVIMED entdecken
EditorialKommentar

Editorial: A Better Perspective on Antipsychotic-Related Hyperprolactinemia in Children and Adolescents

Jeffrey R Strawn, Thomas D Geracioti

Journal of the American Academy of Child & Adolescent Psychiatry · 2023

DOI: 10.1016/j.jaac.2023.05.003 ↗

Kurz gefasst

Editorial in der Zeitschrift Journal of the American Academy of Child & Adolescent Psychiatry, 2023. Verfasst von Jeffrey R Strawn und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Cincinnati College of Medicine, Cincinnati, Ohio. Electronic address: strawnjr@uc.edu. Hauptthemen laut MEDLINE: Antipsychotic Agents, Hyperprolactinemia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 3 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antipsychotic-induced hyperprolactinemia is common in children and adolescents, but this quotidian presence in our clinics should neither reassure us nor make us complacent. The report by Koch and colleagues1 stands out against the landscape of trials describing the adverse effects of psychotropic medications in youth. It goes beyond the typical examination of adverse effects in most clinical trials. The authors followed children and adolescents aged 4 to 17 years who were dopamine-serotonin receptor antagonist naive (≤1-week exposure) or free, and serially evaluated not only serum prolactin concentrations but medication concentrations and side effects for 12 weeks after participants began aripiprazole, olanzapine, quetiapine, or risperidone. This report provides insights into the temporal course of adverse effects, examines differential tolerability among dopamine-serotonin receptor antagonists, links specific adverse effects-galactorrhea, decreased libido, and erectile dysfunction-with prolactin concentrations in youth, and focuses on the clinical aspects of hyperprolactinemia and related adverse effects in children and adolescents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsHyperprolactinemiaMaleFemaleAdolescentChildHumansProlactinDopamineRisperidoneAripiprazole

Substanzen

Antipsychotic AgentsProlactinDopamineRisperidoneAripiprazole

Autor:innen und Institutionen

  • University of Cincinnati College of Medicine, Cincinnati, Ohio. Electronic address: strawnjr@uc.edu.
  • University of Cincinnati College of Medicine, Cincinnati, Ohio.

Zitieren

APA

Strawn, J. R., & Geracioti, T. D. (2023). Editorial: A Better Perspective on Antipsychotic-Related Hyperprolactinemia in Children and Adolescents. Journal of the American Academy of Child & Adolescent Psychiatry. https://doi.org/10.1016/j.jaac.2023.05.003

Vancouver

Strawn JR, Geracioti TD. Editorial: A Better Perspective on Antipsychotic-Related Hyperprolactinemia in Children and Adolescents. Journal of the American Academy of Child & Adolescent Psychiatry. 2023. doi:10.1016/j.jaac.2023.05.003

BibTeX
@article{Strawn2023,
  author = {Strawn, Jeffrey R and Geracioti, Thomas D},
  title = {Editorial: A Better Perspective on Antipsychotic-Related Hyperprolactinemia in Children and Adolescents},
  journal = {Journal of the American Academy of Child & Adolescent Psychiatry},
  year = {2023},
  doi = {10.1016/j.jaac.2023.05.003}
}
Kostenlos starten →